NCT04931823View on ClinicalTrials.gov

Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

March 24, 2021

Primary Completion Date

March 1, 2025

Study Completion Date

March 1, 2025

Conditions
Solid Tumor
Interventions
DRUG

CPO-100

Docetaxel albumin-bound

Trial Locations (8)

15213

University of Pittsburgh Medical Center, Pittsburgh

22031

Virginia Cancer Specialist, Fairfax

28078

Carolina BioOncology Institute, Huntersville

44124

The Cleveland Clinic Foundation, Lyndhurst

75246

University of California Los Angeles, Los Angeles

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

06520

Yale University School of Medicine - Yale Cancer Center, New Haven

Sponsors
All Listed Sponsors
collaborator

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

lead

Conjupro Biotherapeutics, Inc.

INDUSTRY

NCT04931823 - Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter